Listen to Dr. Nirmish Shah discuss the mechanism of action of Oxbryta, how it was designed to target HbS polymerization, and its proposed effect on red blood cell morphology.
For more information about the Oxbryta MOA, watch an additional video How Oxbryta intervenes
Dr. Santosh Saraf explores the Phase 3 HOPE trial, including the trial’s design, study endpoints, and baseline demographics, as well as the study design from the Phase 2a HOPE-KIDS 1 trial.
Go to Video >>
Dr. Santosh L. Saraf reviews the convenient, once-daily oral dosing of Oxbryta, dose adjustment protocols utilized during the Phase 3 HOPE and Phase 2a HOPE-KIDS 1 trials, and topics to discuss with patients when initiating Oxbryta therapy.
Go to Video >>
While not necessary for all patients, dose modifications may be appropriate to help manage adverse reactions in some cases. Watch Dr. Alan Anderson describe the dose adjustment protocols utilized during the Phase 3 HOPE trial.
Go to Video >>
Dr. Nirmish Shah discusses Maria who has an Hb level of 7.0 g/dL, has had 3 VOCs in the past year, and complains of increasing shortness of breath.
Go to Video >>
Dr. Santosh L. Saraf discusses Henry who has an Hb level of 6.5 g/dL and has had 3 VOCs and 2 episodes of acute chest syndrome in the past year.
Go to Video >>
Dr. Alan Anderson discusses Gabriel who has an Hb level of 6.0 g/dL, has had 3 VOCs in the past year, has established microalbuminuria, and complains of yellowing eyes.
Go to Video >>
Listen to Dr. Nirmish Shah discuss the mechanism of action of Oxbryta, how it was designed to target HbS polymerization, and its proposed effect on red blood cell morphology.
For more information about the Oxbryta MOA, watch an additional video How Oxbryta intervenes
Dr. Santosh Saraf explores the Phase 3 HOPE trial, including the trial’s design, study endpoints, and baseline demographics, as well as the study design from the Phase 2a HOPE-KIDS 1 trial.
Go to Video >>
Dr. Santosh L. Saraf reviews the convenient, once-daily oral dosing of Oxbryta, dose adjustment protocols utilized during the Phase 3 HOPE and Phase 2a HOPE-KIDS 1 trials, and topics to discuss with patients when initiating Oxbryta therapy.
Go to Video >>
While not necessary for all patients, dose modifications may be appropriate to help manage adverse reactions in some cases. Watch Dr. Alan Anderson describe the dose adjustment protocols utilized during the Phase 3 HOPE trial.
Go to Video >>
Dr. Nirmish Shah discusses Maria who has an Hb level of 7.0 g/dL, has had 3 VOCs in the past year, and complains of increasing shortness of breath.
Go to Video >>
Dr. Santosh L. Saraf discusses Henry who has an Hb level of 6.5 g/dL and has had 3 VOCs and 2 episodes of acute chest syndrome in the past year.
Go to Video >>
Dr. Alan Anderson discusses Gabriel who has an Hb level of 6.0 g/dL, has had 3 VOCs in the past year, has established microalbuminuria, and complains of yellowing eyes.
Go to Video >>
You are now leaving Global Blood Therapeutics’ site and moving to an external website independently operated and not managed by Global Blood Therapeutics. Global Blood Therapeutics assumes no responsibility for the site(s) you're visiting. If you do not wish to leave this site, click Cancel, or click OK to continue.
A message from Dr. Ted W. Love
President and CEO, Global Blood Therapeutics, Inc.
Thank you for visiting the virtual 62nd ASH® Annual Meeting and Exposition!
Thank you for visiting the virtual 62nd ASH® Annual Meeting and Exposition!
We are proud to participate in this important meeting and appreciate your interest in learning more about GBT and Oxbryta® (voxelotor) tablets. We at GBT share your passion and commitment to improving the lives of patients. Together, we can make a difference.
I encourage you to explore our website to learn more about Oxbryta.
Some of the uses or data for Oxbryta® (voxelotor) tablets described in the attached journal article have not been approved by the Food & Drug Administration.
NEJM does not hold itself responsible for statements made by any contributor. Statements or opinions expressed in NEJM reflect the views of the author(s) and not the official policy of the Massachusetts Medical Society unless so stated. NEJM reprints are not intended as the sole source of clinical information on this topic. Readers are advised to search the NEJM website at www.nejm.org and other medical sources for relevant clinical information on this topic. Reprints of articles published in NEJM are distributed only as free-standing educational material. They are not intended to endorse or promote any organization or its products or services.
If you do not wish to leave this site, click Cancel, or click Ok to continue.
